ANZCTR search results

Laboratory studies indicate that CYT997 is able to potently inhibit myeloma cells from patients with this condition. Given these favourable "test tube" findings, Cytopia has decided to investigate whether CYT997, when given to patients with multiple myeloma, can improve their condition and extend survival from the disease. The effect of CYT997 in patients will be determined from analysis of blood plasma and bone marrow samples and comparison to accepted clinical standards for response in multiple myeloma.

This project will examine three approaches to the management of chronic obstructive pulmonary disease. It will evaluate whether any of the approaches are superior in terms of better outcomes and also which one is most economical relative to its benefits. The three approaches are a self-management approach, a structured respiratory rehabilitation program and standard general medical practice management.

The aim is to promote testing for chlamydia among at-risk 16 – 25 year old Australians. A website about chlamydia will be developed in consultation with young people, and linked to an existing, evaluated health promotion website. Eligible visitors to the chlamydia website will be invited to participate in the study. 1,000 participants will be randomly allocated into one of two groups. The intervention group will be offered confidential email interaction with a nurse or doctor to discuss their needs and barriers surrounding testing for chlamydia. The control group will receive an automated email reply directing them back to the website for information. Both groups will complete a de-identified online questionnaire at baseline and 6 months. The main outcome measure will be whether chlamydia testing took place.

The purpose of the study is to test if an experimental topical drug is effective in reducing under-arm perspiration in people who have excessive under-arm perspiration

This study will evaluate the safety (i.e. incidence and type of adverse events) and efficacy (i.e. as measured by complete clearance) of AS101 administered twice daily topically over a treatment period of up to 16 weeks, or until complete clearance of external genital warts in the treatment area.

Trail to start at RNSH but plans to become multi-centre involving spinal specialist units in Australia and New Zealand

The study will enroll 230 patients in a randomized evaluation of a new stent delivery system developed for use in small coronary arteries. The study device is designed with a low profile, maneuverable delivery system to reach small, distal lesions. This study is designed to show that the new stents are safe and effective when compared to the comparator, commercially-available stent. Follow-up will occur at 30 days, 6, 8, and 12 month intervals for the first year, then annually for the next four years.

Studying the Fellow Eye Effect of ranibizumab (Lucentis) injections for macular degeneration.

This study is a prospective, observational study to be conducted in the (CRGH) Intensive Care Unit (ICU), over a 2 month period. The aim is to determine the minimum patient room size and optimum room configuration required to provide patient care in the Intensive Care Unit. Nursing staff from which written informed consent has been obtained will have their movements recorded during an 8 hour shift, noting their position in the room or bedspace, along with distances walked and time spent in each location, relative to the configuration of the room. Direct nursing care will not be scrutinized; only the nurse’s location in the bed area will be examined. Measurements for different room and bedspace configurations will then be compared to determine the most efficient room layout in terms of flow and distances walked. Room configurations will then be changed to determine if flow and distances walked, and staff satisfaction changes. A questionnaire will be administered asking consenting staff on their satisfaction ratings for the various room configurations.

The purpose of this study is to examine the post operative efficacy and safety of NRT initiated in patients admitted to hospital for coronary artery bypass surgery. We hypothesise that commencing NRT in the immediate post operative phase will be well tolerated by patients, lead to fewer withdrawal symptoms and greater quit rates at 6 months. This pilot randomised control trial is expected to validate the feasibility of conducting a larger scale multi-centre trial that will generate evidence to support the use of NRT as an inpatient initiated secondary prevention strategy in post-operative bypass patients.